# INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

Study · id `cardio:ct-nct07906275` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07906275](<https://clinicaltrials.gov/study/NCT07906275>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07906275

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 800 participants.

## Technical summary

Registry record NCT07906275. Randomized; single masking; primary purpose treatment. Start 2026-12-15 (anticipated); primary completion 2030-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 800 participants (planned count; ClinicalTrials.gov record NCT07906275, source copy `cardio:ctgov-nct07906275-2026-10-30`, retrieved 2026-10-31)
- Planned start: 2026-12-15 (anticipated) (ClinicalTrials.gov record NCT07906275, source copy `cardio:ctgov-nct07906275-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT07906275, source copy `cardio:ctgov-nct07906275-2026-10-30`, retrieved 2026-10-31)
- Completion: 2031-03-31 (anticipated) (ClinicalTrials.gov record NCT07906275, source copy `cardio:ctgov-nct07906275-2026-10-30`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT07906275, source copy `cardio:ctgov-nct07906275-2026-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07906275-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
- Acronym: IMP-ACT
- Condition: Stroke, Acute Ischemic
- Condition: Medium Vessel Occlusion
- Intervention (Procedure): Mechanical Endovascular Thrombectomy
- Intervention (Drug): Intravenous Thrombolysis
- Intervention (Biological): Tenecteplase/Alteplase- depending upon availability at each treating centre
- Lead sponsor: University of Calgary
- Lead sponsor class: OTHER
- Collaborator: The George Institute for Global Health, Australia
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: University of Calgary (`cardio:org-university-of-calgary`)
- Registry lists this organization as a collaborator: The George Institute for Global Health (`core:george-institute`)

## Provenance

Content hash: 7f26cbe651c86a5ec2e9495d665389ee71159c944ca6d2eb4c2a4b97f372cea5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
